{"product_id":"dynavax-pestle-analysis","title":"Dynavax PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Competitive Advantage Starts with This Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock how political, economic, social, technological, legal, and environmental forces are shaping Dynavax’s trajectory—our concise PESTLE highlights key risks and opportunities to sharpen your investment or strategic plan; purchase the full analysis for the complete, fully editable report and actionable insights you can use immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment vaccine mandates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMandatory vaccination policies for healthcare workers and high-risk groups bolster demand for HEPLISAV-B, supporting Dynavax’s U.S. adult hepatitis B vaccine revenue, which rose to $67.3 million in 2024. Dynavax depends on federal and state mandates and procurement contracts to sustain market penetration across jurisdictions. Political leadership changes can alter enforcement or expansion of mandates, creating volatility in uptake and near-term sales forecasts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal health policy shifts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInternational political stability shapes uptake of Dynavax CpG 1018, with WHO procurement and Gavi influence critical while 40% of vaccine demand growth by 2030 is expected in LMICs; navigating complex procurement rules and sanctions risks delays in markets like Russia\/Belarus, where geopolitical tensions raised trade barriers in 2022–24. US alignment with partners can ease exports of proprietary adjuvants, impacting FY2024 revenue streams tied to license deals (Dynavax reported $60M product revenue in 2024).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic health funding levels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFederal allocations to CDC and NIH shape public clinic purchasing power; for example, the 2025 proposed CDC budget rose to about $8.6 billion and NIH to $55.3 billion, directly influencing demand for vaccines distributed via government programs.\u003c\/p\u003e\n\u003cp\u003eBecause roughly 60–70% of US vaccine doses flow through public programs, cuts to healthcare spending could compress Dynavax gross margins by reducing volume and pricing leverage.\u003c\/p\u003e\n\u003cp\u003eConversely, increased funding for preventive care—reflected in recent federal grants and the 2024-25 ARPA-H investments—creates a supportive market for Dynavax revenue expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrade policy and tariffs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe cost of raw materials for vaccine manufacturing is highly sensitive to international trade agreements and tariffs; for example, global vaccine ingredient price volatility rose 8–12% in 2023 amid supply-chain constraints. Political decisions imposing trade barriers could disrupt sourcing of oligonucleotides and lipids used in CpG 1018, risking higher input costs and potential production delays. Dynavax must monitor US-China, US-EU and WTO developments, as tariff adjustments or export controls could raise procurement costs by mid-single digits to double digits depending on scope. Ongoing tariff-related risks could materially affect gross margins and time-to-market for adjuvant-dependent products.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2023 ingredient price volatility 8–12%\u003c\/li\u003e\n\u003cli\u003eTariff\/export-control risks could raise procurement costs mid- to double-digits\u003c\/li\u003e\n\u003cli\u003eMonitor US-China, US-EU, WTO policy shifts\u003c\/li\u003e\n\u003cli\u003ePotential impact on gross margins and time-to-market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug pricing legislation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolitical pressure to control drug costs threatens pricing power for specialized vaccines like Dynavax's HEPLISAV-B; US drug pricing bills in 2024 proposed negotiating authority and price caps that could reduce premiums on branded vaccines by an estimated 10–25% industry-wide.\u003c\/p\u003e\n\u003cp\u003eLegislation enabling government negotiation for biologics could lower long-term HEPLISAV-B margins—Dynavax reported 2024 HEPLISAV-B revenue of ~$227m—so even modest price cuts would hit profitability.\u003c\/p\u003e\n\u003cp\u003eDynavax must intensify advocacy and publish cost-effectiveness analyses showing its two-dose regimen achieves similar or better adherence and protection versus three-dose schedules, citing studies that show 10–30% higher completion rates for two-dose vaccines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 HEPLISAV-B revenue ~$227m\u003c\/li\u003e\n\u003cli\u003ePotential industry price reductions 10–25%\u003c\/li\u003e\n\u003cli\u003eTwo-dose completion rates 10–30% higher vs three-dose\u003c\/li\u003e\n\u003cli\u003eRisk to margins if government negotiation enacted\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDynavax revenue swings on policy, CDC budget, ingredient costs and drug-price reforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical mandates, federal budgets, trade\/tariff shifts and drug-pricing reforms drive Dynavax revenue volatility; 2024 HEPLISAV-B revenue ~$227M, U.S. adult vaccine sales $67.3M, CDC budget ~ $8.6B (2025 proposal), NIH $55.3B, ingredient price volatility +8–12% (2023), potential price cuts 10–25%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHEPLISAV-B rev (2024)\u003c\/td\u003e\n\u003ctd\u003e$227M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. adult vaccine sales (2024)\u003c\/td\u003e\n\u003ctd\u003e$67.3M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDC budget (2025)\u003c\/td\u003e\n\u003ctd\u003e$8.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIngredient price vol (2023)\u003c\/td\u003e\n\u003ctd\u003e+8–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect Dynavax across six dimensions—Political, Economic, Social, Technological, Environmental, and Legal—providing data-backed trends, forward-looking insights, and detailed sub-points tailored to the vaccine\/biotech industry to help executives, investors, and strategists identify risks, opportunities, and actionable scenarios for planning and fundraising.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondensed Dynavax PESTLE insights that can be dropped into presentations or shared across teams for quick alignment on regulatory, market, and technological risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest rate environment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of late 2025, US benchmark interest rates around 5.25–5.50% raise Dynavax’s weighted average cost of capital, increasing projected financing costs for R\u0026amp;D and clinical trials by several hundred basis points versus 2021–22; higher borrowing costs make debt-funded programs more expensive and may slow pipeline acceleration. Investors watch rates closely—rising yields pressure cash burn metrics and leverage ratios, affecting valuations and access to capital.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare insurance coverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe economic viability of HEPLISAV-B depends on reimbursement levels from private insurers and Medicare; in 2024 average Medicare Part B vaccine reimbursement trends and commercial payer rates determine uptake and revenue. Rising patient deductibles—U.S. average deductible for employer plans was about $1,763 in 2024—plus narrower networks can push providers toward lower-cost vaccines. Dynavax negotiates formulary tier placement to limit patient out-of-pocket costs and sustain market share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal supply chain inflation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRising costs for specialized lab equipment and reagents—up 12–18% YoY in 2024 for biopharma inputs per IHS Markit—can compress Dynavax’s margins, forcing tighter cost controls; the company must manage inflation across manufacturing to sustain its pricing strategy given FY2024 gross margin pressures (~40% industry reference). Economic volatility in global logistics, with container rates spiking up to 60% in late 2023–2024, drives strategic stockpiling of critical vaccine components.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLabor market competitiveness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDynavax operates in a tight labor market where demand for scientists and regulatory experts drives premium pay; US biotech median R\u0026amp;D salaries rose ~6% in 2024, and specialized regulatory roles command \u0026gt;$180k median total comp.\u003c\/p\u003e\n\u003cp\u003eTo retain talent Dynavax must offer competitive packages, pressuring margins as pharma wage growth (pharma sector average wage growth ~5–7% in 2023–24) increases G\u0026amp;A and R\u0026amp;D expenses.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh demand for specialized scientists\/regulatory experts\u003c\/li\u003e\n\u003cli\u003eMedian regulatory total comp \u0026gt;$180k (2024)\u003c\/li\u003e\n\u003cli\u003eBiotech R\u0026amp;D salaries +6% (2024)\u003c\/li\u003e\n\u003cli\u003ePharma wage growth 5–7% raises G\u0026amp;A\/R\u0026amp;D costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency exchange fluctuations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAs Dynavax scales adjuvant partnerships globally, exposure to FX volatility rises; the US dollar strengthened ~8% vs. a basket of major currencies in 2024, which can raise local prices and slow uptake of HEPLISAV-B and collaborator programs.\u003c\/p\u003e\n\u003cp\u003eA strong dollar may compress international revenues—Dynavax reported $172m revenue in 2024—while economic instability in markets like Latin America or Southeast Asia can delay milestone payments and royalties, impacting cash flow timing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStrong USD (~+8% in 2024) increases local pricing\u003c\/li\u003e\n\u003cli\u003e2024 revenue $172m—sensitive to FX and payment delays\u003c\/li\u003e\n\u003cli\u003eMarket instability can postpone royalties\/milestones\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigher US rates, rising costs and strong USD squeeze margins for $172M biotech\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigher US rates (5.25–5.50% late-2025) raise WACC and financing costs; Medicare\/commercial reimbursement and $1,763 avg deductible (2024) drive HEPLISAV-B uptake; input costs +12–18% (2024) and logistics spikes compress margins; biotech pay +6% (2024), regulatory comp \u0026gt;$180k increase OPEX; strong USD +8% (2024) pressures international revenue (2024 revenue $172m).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS rates\u003c\/td\u003e\n\u003ctd\u003e5.25–5.50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAvg deductible\u003c\/td\u003e\n\u003ctd\u003e$1,763\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInput cost rise\u003c\/td\u003e\n\u003ctd\u003e12–18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotech pay\u003c\/td\u003e\n\u003ctd\u003e+6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUSD strength\u003c\/td\u003e\n\u003ctd\u003e+8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$172m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eDynavax PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Dynavax PESTLE Analysis document you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic planning or investment review.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751251620217,"sku":"dynavax-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/dynavax-pestle-analysis.png?v=1772229309","url":"https:\/\/growthsharematrix.com\/products\/dynavax-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}